Related Experiment Videos
Risk-benefit assessment of carbamazepine in children
1Division of Child Neurology, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Insights
Carbamazepine is an effective antiepileptic drug for epilepsy in adults and children. While pharmacokinetic profiles are similar, children have a shorter half-life, and common side effects are dose-related and often temporary.
Area of Science:
- Pharmacology
- Neurology
- Pediatrics
Background:
- Carbamazepine is a widely used antiepileptic medication.
- Its efficacy is established for partial and generalized convulsive epilepsy.
- Understanding its use in pediatric populations is crucial.
Purpose of the Study:
- To review the pharmacokinetic profile of carbamazepine in children compared to adults.
- To outline common and idiosyncratic adverse effects.
- To highlight potential cognitive and behavioral advantages.
Main Methods:
- Literature review of pharmacokinetic data.
- Analysis of adverse event reporting.
- Comparison of clinical outcomes and side effect profiles.
Main Results:
- Pediatric pharmacokinetic profile similar to adults, with a shorter half-life (6-12 hours vs. 15 hours).
- Autoinduction is present in both populations.
- Common adverse effects are dose-related neurological symptoms (up to 50%), usually transient.
- Benign leucopenia (10-12%) is distinct from rare aplastic anemia.
- Potential cognitive and behavioral benefits noted.
Conclusions:
- Carbamazepine is a significant antiepileptic treatment option for both pediatric and adult patients.
- Awareness of pharmacokinetic differences and adverse effect profiles is essential for effective management.
- Its favorable side effect profile and potential cognitive benefits support its continued use.
Abstract:
Carbamazepine is an effective antiepileptic drug for the treatment of partial and convulsive generalised epilepsy in adults and children. The pharmacokinetic profile in children is similar to that in adults, but the half-life in long term paediatric therapy is between 6 and 12 hours, compared with 15 hours in adults. Autoinduction is present. The most common adverse effects are neurological and dose-related, and occur in up to 50% of patients treated, usually on dosage initiation or dose elevation. Most dissipate over time and require no alteration in dosage. Idiosyncratic effects include hypersensitivity, hepatic and haematological reactions. A benign leucopenia occurs in 10 to 12% of adults and children and appears to be unrelated to aplastic anaemia which occurs in approximately 1 in 575,000 treated patients per year. Carbamazepine is reported to have cognitive and behavioural advantages over other antiepileptic drugs. Overall, carbamazepine has become a major antiepileptic drug in children as well as adults.